SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
17 12월 2007 - 8:00PM
PR Newswire (US)
SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals,
Inc. (NASDAQ:SGXP) today announced that Joseph L. Turner has been
appointed to the company's Board of Directors. Mr. Turner brings
over 25 years of management experience in the pharmaceutical
industry and will also serve on the company's audit committee. "We
are delighted to welcome Joe to the Board," said Dr. Christopher S.
Henney, Chairman of the Board of Directors of SGX. "As a seasoned
financial and operations executive with considerable experience in
the pharmaceutical and biotechnology industry, we look forward to
his insights as the company continues on its path to bringing
compounds into the clinic." Mr. Turner was previously the Senior
Vice President of Finance and Administration and Chief Financial
Officer at Myogen, a therapeutics company focused on cardiovascular
disease, until its sale to Gilead Sciences, Inc. in November 2006.
Prior to Myogen, he worked at Centaur Pharmaceuticals, a
biopharmaceutical company, where he served as Vice President,
Finance and Chief Financial Officer. Before Centaur, Mr. Turner
served as Vice President, Finance and Chief Financial Officer of
Cortech, Inc. and before that spent 12 years with Eli Lilly and
Company, where he held a variety of financial management positions
both within the United States and abroad. Mr. Turner holds a M.A.
in molecular, cellular and developmental biology from the
University of Colorado and a M.B.A. from the University of North
Carolina. Separately, SGX also announced that Vijay Lathi, a member
of the Board of Directors since May 2002, resigned as a director of
the company effective December 31, 2007. Mike Grey, President and
Chief Executive Officer of SGX said, "I would like to take this
opportunity to thank Vijay for his contributions to the SGX Board
and his support of the company over the past five years. We have
appreciated his advice and guidance and wish him well as he devotes
his time to earlier stage companies in the New Leaf portfolio."
About SGX Pharmaceuticals SGX Pharmaceuticals is a biotechnology
company focused on the discovery, development and commercialization
of innovative cancer therapeutics. The SGX oncology pipeline
includes drug candidates from its FAST(TM) drug discovery platform,
such as next generation BCR-ABL inhibitors being developed by SGX
and in partnership with Novartis and cMET tyrosine kinase
inhibitors, including SGX523, and JAK2 inhibitors. More information
on the pipeline and drug discovery platform can be found at
http://www.sgxpharma.com/ and in the Company's various filings with
the Securities and Exchange Commission. Forward Looking Statements
Statements in this press release that are not strictly historical
in nature are forward-looking statements. These statements include,
but are not limited to, statements regarding bringing compounds
into the clinic and the ability to discover, develop and
commercialize cancer therapeutics. These statements are only
predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization. For a discussion of these and other factors,
please refer to the risk factors described in the Company's annual
report on Form 10-K for the year ended December 31, 2006, the
Company's quarterly report on Form 10-Q for the three and nine
months ended September 30, 2007, as well as other filings with the
Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and SGX undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof. Contact: Todd Myers Jason
Spark Chief Financial Officer Media & Investor Relations SGX
Pharmaceuticals Porter Novelli Life Sciences (858) 558-4850 (619)
849-6005 DATASOURCE: SGX Pharmaceuticals, Inc. CONTACT: Todd Myers,
Chief Financial Officer of SGX Pharmaceuticals, +1-858-558-4850; or
Jason Spark, Media & Investor Relations, of Porter Novelli Life
Sciences, +1-619-849-6005, for SGX Pharmaceuticals, Inc. Web site:
http://www.sgxpharma.com/
Copyright
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Sgx Pharmaceuticals (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Sgx Pharmaceuticals (MM) News Articles